Edition:
United Kingdom

Gensight Biologics SA (SIGHT.PA)

SIGHT.PA on Paris Stock Exchange

2.61EUR
9:44am GMT
Change (% chg)

€0.24 (+10.13%)
Prev Close
€2.37
Open
€2.48
Day's High
€2.70
Day's Low
€2.34
Volume
352,033
Avg. Vol
104,447
52-wk High
€7.68
52-wk Low
€1.34

Summary

Name Age Since Current Position

Bernard Gilly

Chairman of the Board, Chief Executive Officer, Co-Founder

Thomas Gidoin

Chief Financial Officer

Jean-Philippe Combal

Chief Operating Officer

Didier Pruneau

Chief Scientific Officer

Nitza Thomasson

Head of Preclinical Development

Florent Gros

Director

Genghis Lloyd-Harris

54 Director

Guido Magni

64 Director

Peter Goodfellow

63 Independent Director

Michael Wyzga

63 Independent Director

Biographies

Name Description

Bernard Gilly

Dr. Bernard Gilly is Executive Chairman of the Board, Chief Executive Officer and Co-Founder of Gensight Biologics SA. He was the Chairman and CEO of Fovea Pharmaceuticals, a biotech company he founded in 2005 and which he sold in 2009 to Sanofi, and then became Senior Vice-President of the Ophthalmology Division of Sanofi until March 2012. Prior to Fovea, he was a Partner at Sofinnova Partners from 2000 to November 2005. He founded and invested in several companies, including Sequoia Pharmaceuticals (USA), Faust Pharmaceuticals (France) and Cellzome (Germany). Prior to joining Sofinnova, he served as President and CEO of Transgene and before that, he spent six years as VP R&D at Pasteur-Merieux-Connaught, the vaccine company that since then became Sanofi Pasteur. He was managing scientists and development engineers in three facilities (France, USA and Canada) and was a member of the Executive Committee of the group.

Thomas Gidoin

Mr. Thomas Gidoin is Chief Financial Officer of Gensight Biologics SA. He brings significant corporate finance and leadership experience to GenSight. Since 2012, he led the Corporate Finance team at DBV Technologies, participating in public offerings and private placements, including the dual listing of the company on the NASDAQ Global Select Market. Prior to that, he worked at Ipsen from 2008 to 2011, as a Senior Financial Analyst within the Group Operations division and later as UK Operations Controller in London.

Jean-Philippe Combal

Dr. Jean-Philippe Combal is Chief Operating Officer of Gensight Biologics SA. From 2011 to early 2014, Dr. Combal was managing preclinical and clinical product and portfolio development at Galderma International S.A. for its Dermatology Strategic Therapeutic Area. Prior to joining Galderma International S.A., he served as Vice President, Director of Development at Fovea, and then held the position of Vice President, Strategic Marketing for the Ophthalmic Division at Sanofi. Dr. Combal received a Pharm.D and Ph.D. from Paris XI and Paris V University, respectively, a master’s degree from ESCP in strategic marketing and general management degree from CEDEP-INSEAD.

Didier Pruneau

Dr. Didier Pruneau is the Chief Scientific Officer of Gensight Biologics SA. He holds a Ph.D. in Biochemistry and Master Degree (Valedictorian) in Pharmacology (Universite Paris V), and Post-doctoral fellowship in Cardiovascular Pharmacology (Baker Medical Research Institute, Melbourne, Australia). He is the author or co-author of seventy nine peer-reviewed scientific publications and about seventy scientific communications. His previous roles include Head of the Department of Pharmacology (Fournier Pharma), Head of Scientific Operations (Fovea Pharmaceuticals), and Head of Scientific Evaluation and Drug Discovery Ophthalmology Division (Sanofi).

Nitza Thomasson

Dr. Nitza Thomasson is the Head of Preclinical Development of Gensight Biologics SA. After six years of academic research (PhD in cognitive neurosciences, La Salpetriere, Paris and Rush Hospital, Chicago), she joined the pharmaceutical industry in 2001 and spent seven years at Servier Pharmaceuticals as Head of Biological Studies in Neurospychiatry Department. Early 2009, she joined Fovea Pharmaceuticals to lead the development of compounds in ophthalmology including nonclinical, CMC, clinical and regulatory aspects. In September 2010, she became Director of Preclinical Department of Sanofi Ophthalmology Business Division after the acquisition by Sanofi-Aventis of Fovea Pharmaceuticals, being responsible for CMC, DMPK and toxicity regulatory program. Dr. Thomasson received a Ph.D. in neuroscience from Paris VI—La Salpetriere.

Florent Gros

Mr. Florent Gros is Board Member of Gensight Biologics SA. He graduated from Ecole Superieure de Biotechnologie de Strasbourg. He is Managing Director at Novartis Venture Fund, a corporation that is affiliated with Novartis Pharma AG. He has held various positions in the intellectual property and venture areas at Nestlé S.A., Pasteur Merieux Connaught S.A. and Novartis S.A.. He holds European and French patent law degrees and a Masters in Private Law. Mr. Gros currently serves on the board of Applied Immune Technologies Ltd, Atlas Genetics Ltd, Merus B.V., MyoPowers Medical Technologies S.A., Anokion S.A., Opsona Therapeutics Ltd. and Vaxin Inc.

Genghis Lloyd-Harris

Dr. Genghis Lloyd-Harris is Board Member of Gensight Biologics SA. He is Partner at Abingworth LLP. Prior to joining Abingworth in 2004, Dr. Lloyd-Harris was a managing director in the European equity research group at Credit Suisse First Boston (CSFB) where he was responsible for coverage of the European biotechnology industry and was ranked first for Pan-European Biotechnology in the Institutional Investor surveys each year from 2001 to 2003. Before joining equity research at CSFB, he worked for CSFB’s health care group in the investment banking division in New York. Dr. Lloyd-Harris was previously a paediatrician in Melbourne, Australia. Dr. Lloyd-Harris holds a medical degree from the University of Liverpool, UK; a Ph.D. in clinical pharmacology from the University of Melbourne, Australia; and an MBA from Harvard Business School. Dr. Lloyd-Harris currently serves on the board of Avillion LLP, Wilson Therapeutics AB and Abingworth LLP, and has previously served on the boards of several companies including Solexa Inc, Novexel SA, HBI Ltd, Syntaxin Ltd, InPharmatica Ltd and Synosia AG.

Guido Magni

Dr. Guido Magni is Board Member of Gensight Biologics SA. He is a Partner with Versant Ventures, based in Basel, Switzerland. Dr. Magni previously served as a Managing Director of EuroVentures, a Versant incubator, where he was involved with several biotech investments including Synosia Therapeutics AG, which was sold to Biotie Therapeutics AG, or Biotie, Flexion Therapeutics AG and Okairos AG, which was sold to GSK. Dr. Magni was previously Global Head of Medical Sciences in Roche, in the Global Drug Development department. During his twelve years in this position, Dr. Magni oversaw the development and the registration of a large number of new chemical and biological entities including Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva. Dr. Magni currently serves in the board of Biotie, Piqur Therapeutics AG and AM Pharma B.V.. Dr. Magni has an M.D. degree from the University of Padua and a Ph.D. in neuro-pharmacology from the University of Rome.

Peter Goodfellow

Dr. Peter Goodfellow is Independent Board Member of Gensight Biologics SA. He has worked in both Academia and Industry. He spent 13 years at Imperial Cancer Research Institute in London (now part of CRUK) and 4 years as Balfour Professor of Genetics at Cambridge University. Subsequently, he worked for a decade in the pharmaceutical industry, serving first as worldwide head of Research for SmithKline Beecham and then Senior Vice-President of Discovery Research at GlaxoSmithKline. He is also a Founder of two biotechnology companies. Amongst other honors, he has been elected as a Fellow of The Royal Society, EMBO and the Academy of Medical Sciences. He has been awarded the Louis Jeantet Prize for Medicine (with Dr. R Lovell-Badge), the Francis Amory Prize of the American Academy of Arts and Sciences (with Dr. R.Lovell-Badge) and an Honorary Doctorate in Science (honoris causa) from Bristol University. He is a visiting professor at Birkbeck College, University College London, Bristol University, University of Kent and Hong Kong University (Mok Hing-Liu Visiting Professor).

Michael Wyzga

Mr. Michael Wyzga is Independent Board Member of Gensight Biologics SA. He is currently a biotechnology consultant and has extensive experience in the biotechnology industry. From 2011 to 2013, he was the President, Chief Executive Officer and a member of the Board of Directors of Radius Health, Inc. Prior to that, he served as Chief Financial Officer of Genzyme, where he worked for 12 years. He currently serves on the Board of Directors of Oncomed Pharmaceuticals, Inc., of Akebia Therapeutics, Inc. and of Exact Sciences Corp.; Mr. Wyzga received an M.B.A. from Providence College and a B.S. from Suffolk University.